Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
AstraZeneca PLC ADR TradeGate Stock Price Today | NASDAQ AZNPy Live Ticker - Investing.com
Investing.com· 2 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 7 days agoTruqap™ (capivasertib) plus fulvestrant now available in Canada Canada NewsWire MISSISSAUGA, ON, May 31, 2024 MISSISSAUGA, ON, May 31, 2024 /CNW/ - AstraZeneca is pleased ...
Cramer's Lighting Round: ‘You've got a winner' with Astra Zeneca
NBC Los Angeles· 6 days ago“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WHTC 1450 Holland· 5 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 3 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
The Motley Fool via AOL· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth outside of obesity, so a future win in that segment would just be the icing on the cake. 2. < ...
Germany’s ITM raises $205M as radiopharma field booms
BioPharma Dive via Yahoo Finance· 24 hours agoBristol Myers spent $4.1 billion to buy RayzeBio; AstraZeneca paid $2 billion for Fusion...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 7 days agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
Move over 'Magnificent 7,' the 'Fantastic 5' may offer higher earnings and return potential
CNBC· 21 hours agoLooking for a less risky way to find growth stocks amid all the artificial intelligence hype?...